News
-
Activaero has announced that its FAVORITE (flow and volume regulated inhalation technology) system is being used for additional Phase 1 studies of Ablynx’s Nanobody ALX-0171 for the treatment of respiratory syncytial virus (RSV). Results from… Read more . . .
-
MDI component manufacturer Presspart has hired Sameer Kunte as its new Customer Services Manager for India, the company said. Kunte has extensive experience with OINDP device development and has worked previously for 3M, Dr. Reddy’s,… Read more . . .
-
The final article in a 3-part series . . . Read more Read more . . .
-
Insmed Incorporated has announced a proposed underwritten public offering of $60 million of its common stock to fund continued clinical development, regulatory efforts, and commercialization of Arikace inhaled liposomal amikacin, its lead product. The company… Read more . . .
-
GlaxoSmithKline and Theravance have withdrawn the application for their fluticasone furoate/vilanterol DPI for the treatment of COPD from the Japanese New Drug Application (JNDA) for the drug, the companies say. Review of the JNDA, which… Read more . . .
-
GlaxoSmithKline has announced that the Breo Ellipta fluticasone furoate/vilanterol DPI has been approved for the treatment of COPD in Canada. GlaxoSmithKline Inc. President Paul Lirette said, “For over forty years, GlaxoSmithKline has been at the… Read more . . .
-
Inhaler testing automation supplier Astech Projects is celebrating its 18th anniversary on July 18, 2013 by offering a free consultation and proposal for a laboratory automation system. The company manufactures semi- to fully-automated dose content… Read more . . .
-
The US District Court for the Southern District of New York has issued a final judgment and order affirming the validity of five patents related to Mylan’s Perforomist formoterol fumarate inhalation solution and stating that… Read more . . .
-
According to multi-industry laboratory company Intertek, it has acquired OINDP testing specialist Melbourn Scientific. In its announcement, Intertek cites Melbourn’s “profound expertise in all aspects of characterization of orally inhaled and intra-nasal products (OINDP)” and… Read more . . .
-
Trimel Pharmaceuticals has announced the acceptance of its NDA for CompleoTRT bioadhesive intranasal gel testosterone and the PDUFA date, February 28, 2014. The company announced submission of the NDA at the end of April 2013.… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 9-June 10: Nasal Drug Delivery Symposium: Current Status and Future Opportunities, Stockholm, Sweden
June 10: SMI.London 2026, London, UK